Tilray Brands Inc (NASDAQ: TLRY) soared on market open today after coming in ahead of Street estimates for its fiscal Q1, with net income printing at $1.5 million and revenue climbing to a record $210... ...

Core Insights - The article emphasizes the importance of conducting thorough research before making investment decisions, highlighting that past performance does not guarantee future results [2][3] Company Analysis - No specific companies are mentioned in the article, but it stresses the need for investors to evaluate their own positions and consult financial advisors [2][3] Industry Overview - The article reflects on the broader investment landscape, indicating that investing carries inherent risks, including the potential loss of principal [2][3]

Key Points Tilray was "supposed" to lose money in Q1. It delivered a surprise profit instead. Earnings in Q1 were a positive $1.5 million. 10 stocks we like better than Tilray Brands › Tilray Brands (NASDAQ: TLRY) stock exploded higher after reporting a surprise profit in its fiscal Q1 earnings report Thursday. Heading into the report, analysts forecast Tilray would lose $0.04 per share on $205.8 million in quarterly revenue. Instead, Tilray broke even on earnings with a $0.00 profit, while its r ...

Core Insights - Tilray Brands Inc. reported better-than-expected first-quarter 2026 earnings, achieving break-even compared to a consensus loss of 2 cents per share, with adjusted net income of $3.9 million versus an adjusted net loss of $(6.1) million [1] - Adjusted EBITDA increased by 9% year over year to $10.2 million, up from $9.3 million [1] Revenue Performance - Net revenue rose by 5% to $209.5 million, exceeding the consensus estimate of $204.55 million [2] - Cannabis net revenue increased by 5% to $64.5 million, compared to $61.2 million [2] - Beverage net revenue was slightly down at $55.7 million compared to $56.0 million [2] - Wellness net revenue increased to $15.2 million from $14.8 million [2] - Distribution net revenue grew to $74.0 million from $68.1 million [2] Margin and Debt Management - Gross margin contracted from 30% to 27% [3] - The company reduced its debt by $7.7 million, improving its balance sheet, with a net debt to trailing twelve months adjusted EBITDA ratio of 0.07x [4] - Tilray holds a cash balance of $264.8 million, providing flexibility for strategic opportunities [4] Market Activity - Tilray's stock surged by 29.36%, reaching $2.23 [5] - The company announced the expansion of its Tilray Craft portfolio in Germany with five new cannabis flower products [5]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2][3] - The news team covers key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - Proactive focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [2][3] Group 2 - The team delivers news and insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] - Proactive adopts technology to enhance workflows and improve content production [4][5] - All content published by Proactive is edited and authored by humans, ensuring adherence to best practices in content production and search engine optimization [5]

Core Insights - U.S. stocks experienced a decline, with the Dow Jones index dropping approximately 100 points on Thursday [1] - Tilray Brands, Inc. reported better-than-expected first-quarter financial results, with adjusted earnings of $0.00 per share, surpassing market expectations of a loss of $0.02 per share [1] - Tilray's sales reached $209.501 million, exceeding estimates of $204.549 million, leading to a 30% increase in its share price to $2.2397 [1] Company Performance Highlights - Diginex Limited surged 23% to $38.13 after a 28% increase on Wednesday [4] - NOVONIX Limited gained 22.3% to $2.3650 [4] - Critical Metals Corp. rose 19.2% to $14.07 [4] - Serve Robotics Inc. increased by 18.5% to $16.29 following a strategic partnership with DoorDash for autonomous robot deliveries [4] - POMDOCTOR LIMITED gained 17.1% to $4.7206 [4] - Akero Therapeutics, Inc. rose 16.6% to $54.23 after announcing its acquisition by Novo Nordisk for up to $5.2 billion [4] - Byrna Technologies Inc. increased by 15.8% to $26.42 after reporting better-than-expected quarterly EPS results [4] - Ramaco Resources, Inc. rose 11.3% to $46.19 [4] - UiPath Inc. gained 10.5% to $17.22, shifting focus from traditional RPA to "agentic" automation with AI integration [4] - Energy Fuels Inc. rose 9.9% to $19.76 [4] - Albemarle Corporation jumped 7.9% to $98.94 [4] - ABIVAX Société Anonyme gained 7.8% to $93.29 [4] - TeraWulf Inc. increased by 7.6% to $13.25 [4] - Delta Air Lines, Inc. rose 6.1% to $60.60 after reporting better-than-expected third-quarter results and raising FY25 EPS outlook [4]

Financial Data and Key Metrics Changes - The company reported record first-quarter net revenue of $210 million, a 5% increase year over year, driven by increased cannabis sales in Canada and international markets [31][36] - Net income for the quarter was $1.5 million, compared to a net loss of $34.7 million in the prior year period, indicating a significant turnaround in profitability [35][36] - Adjusted EBITDA for the quarter improved to $10.2 million from $9.3 million last year, reflecting operational efficiency [36] Business Line Data and Key Metrics Changes - Cannabis revenue increased by 5% year over year to $64.5 million, supported by a 12% growth in adult use gross revenue and a 10% growth in international cannabis [31][36] - Beverage revenue reached $55.7 million, impacted by SKU rationalization but supported by new product contributions [32][36] - Wellness revenue grew by 3% year over year to CAD 15.2 million, driven by innovations in health-focused products [32][36] Market Data and Key Metrics Changes - The Canadian cannabis business reported revenue up 4% year over year to $51 million, reinforcing its position as the largest legal cannabis company in Canada by revenue [12][36] - International cannabis revenue grew by 10% year over year to $13.4 million, despite permit challenges in Portugal [14][36] - The distribution segment's revenue increased by 9% year over year to CAD 74 million, primarily due to a stronger euro [32][36] Company Strategy and Development Direction - The company aims to leverage its global platform to drive innovation in cannabis, beverage, and wellness sectors, focusing on sustainable growth and operational efficiency [5][7] - The strategic focus includes optimizing the craft beer SKU portfolio under Project Four Twenty, which has already realized $25 million in annual savings [20][21] - The company is well-positioned to capture growth opportunities in the U.S. medical cannabis market, anticipating a potential market share of 3% to 5% in a $10 billion market [11][36] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the evolving regulatory landscape for cannabis, particularly in the U.S. and Europe, which could enhance patient access and market opportunities [10][11] - The company is confident in its ability to adapt to regulatory changes and is committed to continuous innovation and portfolio expansion [28][36] - Management acknowledged the challenges faced in the beverage segment but emphasized the long-term potential for growth and profitability [20][36] Other Important Information - The company reduced its outstanding debt by $7.7 million during the quarter, bringing its net debt to $3.9 million, which enhances financial flexibility for strategic opportunities [36][37] - The company has built a diversified global platform with over 40 unique brands in more than 20 countries, positioning itself as a leader in the cannabis, beverage, and wellness markets [8][9] Q&A Session Summary Question: International growth opportunities and permit delays - Management noted progress in obtaining permits in Portugal and expressed optimism about increasing production capacity in both Portugal and Germany [41][43][44] Question: Rescheduling opportunities in the U.S. - Management indicated readiness to leverage existing infrastructure and explore partnerships or acquisitions to capture opportunities in the U.S. medical cannabis market [48][51] Question: Canadian adult use market dynamics - Management highlighted a 1.3% decline in overall market pricing, with their pricing up 2% and volume growth of 6.5%, indicating strong performance relative to the market [67][70] Question: Beverage segment profitability improvement plans - Management discussed ongoing efforts in SKU rationalization and integration of acquired brands to improve margins in the beverage segment [75][78] Question: Managing risks in Portugal and Germany - Management emphasized commitment to the Portuguese market while also having contingency plans in Germany, including the ability to ship from Canada [81][84][90]

Core Insights - Tilray Brands, Inc. reported break-even quarterly earnings per share, surpassing the Zacks Consensus Estimate of a loss of $0.03, and improved from a loss of $0.04 per share a year ago, resulting in an earnings surprise of +100.00% [1] - The company posted revenues of $209.5 million for the quarter ended August 2025, exceeding the Zacks Consensus Estimate by 1.29%, and showing an increase from year-ago revenues of $200.04 million [2] - Tilray Brands shares have increased approximately 29.3% since the beginning of the year, outperforming the S&P 500's gain of 14.8% [3] Earnings Outlook - The future performance of Tilray Brands' stock will largely depend on management's commentary during the earnings call and the company's earnings outlook, including current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the coming quarter is -$0.03 on revenues of $215.9 million, and -$0.11 on revenues of $877.28 million for the current fiscal year [7] Industry Context - The Medical - Products industry, to which Tilray Brands belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

[Q1 Fiscal Year 2026 Performance Overview](index=1&type=section&id=Q1_FY2026_Performance_Overview) Tilray Brands reported strong first quarter fiscal 2026 results, achieving record net revenue and net income, driven by operational efficiencies and a focus on profitability [Headline Summary](index=1&type=section&id=Headline_Summary) Tilray Brands reported strong first quarter fiscal 2026 results, achieving record net revenue and net income, driven by operational efficiencies and a focus on profitability Q1 FY2026 Performance Overview | Metric | Q1 FY2026 (Aug 31, 2025) | Q1 FY2025 (Aug 31, 2024) | Change (YoY) | % Change (YoY) | | :------------------------- | :----------------------- | :----------------------- | :----------- | :------------- | | Net Revenue | $210 million | $200 million | +$10 million | +5% | | Net Income | $1.5 million | $(34.7) million | +$36.2 million | +104% | | Adjusted EBITDA | $10 million | $9.3 million | +$0.7 million | +9% | | Net Cash Used in Operations| $(1.3) million | $(35.3) million | +$34 million | -96% (Improvement) | | Cash Balance | $265 million | - | - | - | | Net Debt | $4 million | - | Reduced | - | - Canadian Adult-Use Cannabis Gross Revenue increased **12%**, maintaining the **1 position** in revenue and expanding market share[1](index=1&type=chunk) - International Cannabis Revenue grew **10%** year-over-year[1](index=1&type=chunk) - Reiterated Fiscal Year 2026 Adjusted EBITDA Outlook of **$62 Million – $72 Million**[1](index=1&type=chunk) [CEO Commentary](index=1&type=section&id=CEO_Commentary) CEO Irwin D. Simon highlighted the effectiveness of Tilray's strategic vision and disciplined execution, emphasizing record Q1 net revenue, net income, and a fortified balance sheet as proof points of sustainable growth and operational excellence - Record Q1 net revenue of **$210 million**, delivering net income, and fortifying the balance sheet are proof points of commitment to sustainable growth, operational excellence, and unlocking shareholder value[2](index=2&type=chunk) - Confidence in Tilray's ability to seize transformative opportunities, especially with the U.S. exploring cannabis rescheduling and the evolving European cannabis landscape[2](index=2&type=chunk) - Tilray's global platform, proven expertise in medical and adult-use cannabis, and trusted partnerships position it as a leader in the global cannabis, beverage, and wellness sectors[2](index=2&type=chunk) [Financial Highlights](index=1&type=section&id=Financial_Highlights) Tilray Brands demonstrated significant financial improvements in Q1 FY2026, particularly in profitability, with a shift from net loss to net income and a substantial increase in adjusted EBITDA, alongside improved cash flow from operations [Key Consolidated Financial Metrics](index=1&type=section&id=Key_Consolidated_Financial_Metrics) Tilray Brands demonstrated significant financial improvements in Q1 FY2026, particularly in profitability, with a shift from net loss to net income and a substantial increase in adjusted EBITDA, alongside improved cash flow from operations Consolidated Financial Performance (Q1 FY2026 vs. Q1 FY2025) (in millions of US dollars) | Metric | Q1 FY2026 (Aug 31, 2025) | Q1 FY2025 (Aug 31, 2024) | Change (YoY) | % Change (YoY) | | :------------------------- | :----------------------- | :----------------------- | :----------- | :------------- | | Net Revenue | $209.5 million | $200.0 million | +$9.5 million | +5% | | Gross Profit | $57.5 million | $59.7 million | $(2.2) million | (4)% | | Gross Margin | 27% | 30% | (3) ppts | - | | Net Income (Loss) | $1.5 million | $(34.7) million | +$36.2 million | +104% | | Adjusted Net Income (Loss) | $3.9 million | $(6.1) million | +$10.0 million | +165% | | Adjusted EBITDA | $10.2 million | $9.3 million | +$0.9 million | +9% | | Cash Used in Operations | $(1.3) million | $(35.3) million | +$34.0 million | -96% (Improvement) | [Balance Sheet Update](index=2&type=section&id=Balance_Sheet_Update) Tilray Brands successfully reduced its total outstanding debt in Q1 FY2026, leading to a significantly improved net debt to adjusted EBITDA ratio and maintaining a strong cash balance for strategic flexibility - Total outstanding debt reduced by **$7.7 million** in the first quarter[5](index=5&type=chunk) - Net debt to trailing twelve months adjusted EBITDA ratio reduced to **0.07x**[5](index=5&type=chunk) - Cash balance of **$264.8 million** provides flexibility for strategic opportunities[5](index=5&type=chunk) [About Tilray Brands](index=2&type=section&id=About_Tilray_Brands) Tilray Brands is a global lifestyle and consumer packaged goods company operating across Canada, the U.S., Europe, Australia, and Latin America, leading in the cannabis, beverage, wellness, and entertainment sectors [Company Overview](index=2&type=section&id=Company_Overview) Tilray Brands is a global lifestyle and consumer packaged goods company operating across Canada, the U.S., Europe, Australia, and Latin America, leading in the cannabis, beverage, wellness, and entertainment sectors - Tilray Brands is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America[7](index=7&type=chunk) - The company is a transformative force at the nexus of cannabis, beverage, wellness, and entertainment[7](index=7&type=chunk) - Tilray's platform supports over **40 brands** in over **20 countries**, including comprehensive cannabis offerings, hemp-based foods, and craft beverages[7](index=7&type=chunk) [Use of Non-GAAP Financial Measures](index=3&type=section&id=Use_of_Non-GAAP_Financial_Measures) Tilray Brands utilizes several non-GAAP financial measures, such as Adjusted gross margin, Adjusted EBITDA, and Adjusted net income, to provide investors with additional insights into operational trends and period-over-period comparisons [Non-GAAP Definitions and Rationale](index=3&type=section&id=Non-GAAP_Definitions_and_Rationale) Tilray Brands utilizes several non-GAAP financial measures, such as Adjusted gross margin, Adjusted EBITDA, and Adjusted net income, to provide investors with additional insights into operational trends and period-over-period comparisons - Non-GAAP measures provide useful additional information to investors about current trends and are useful for period-over-period comparisons, but should not be considered in isolation or as a substitute for GAAP measures[13](index=13&type=chunk) - Key non-GAAP measures include Adjusted gross margin, Adjusted gross profit, Adjusted EBITDA, Adjusted net income (loss), Adjusted net income (loss) per share, free cash flow, adjusted free cash flow, constant currency presentations of revenue, cash and marketable securities, net debt, and net debt to adjusted EBITDA[13](index=13&type=chunk) - The company is unable to reconcile certain forward-looking non-GAAP measures to GAAP without unreasonable efforts due to the unpredictability of certain impacting items[14](index=14&type=chunk) [Consolidated Financial Statements](index=4&type=section&id=Consolidated_Financial_Statements) This section presents Tilray's consolidated financial statements, including the statements of financial position, net income (loss), and cash flows, providing a comprehensive overview of the company's financial health and performance [Consolidated Statements of Financial Position](index=4&type=section&id=Consolidated_Statements_of_Financial_Position) Tilray's balance sheet as of August 31, 2025, shows an increase in total assets and stockholders' equity compared to May 31, 2025, primarily driven by higher cash and cash equivalents, while total liabilities decreased Key Balance Sheet Items (in thousands of US dollars) | Metric | August 31, 2025 | May 31, 2025 | Change | | :-------------------------- | :-------------- | :----------- | :----- | | Cash and cash equivalents | $264,828 | $221,666 | +$43,162 | | Total current assets | $701,140 | $688,626 | +$12,514 | | Total assets | $2,082,646 | $2,074,327 | +$8,319 | | Total current liabilities | $267,632 | $280,303 | $(12,671) | | Total liabilities | $561,988 | $584,752 | $(22,764) | | Total stockholders' equity | $1,520,658 | $1,489,575 | +$31,083 | [Condensed Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss)](index=5&type=section&id=Condensed_Consolidated_Statements_of_Net_Income_Loss) For Q1 FY2026, Tilray reported a significant turnaround from a net loss to a net income, driven by increased net revenue and a substantial reduction in total operating expenses, particularly amortization and changes in fair value of contingent consideration Condensed Consolidated Statements of Net Income (Loss) (in thousands of U.S. dollars) | Metric | Q1 FY2026 (Aug 31, 2025) | Q1 FY2025 (Aug 31, 2024) | Change (YoY) | % Change (YoY) | | :---------------------------------- | :----------------------- | :----------------------- | :----------- | :------------- | | Net revenue | $209,501 | $200,044 | +$9,457 | +5% | | Cost of goods sold | $152,032 | $140,338 | +$11,694 | +8% | | Gross profit | $57,469 | $59,706 | $(2,237) | (4)% | | Total operating expenses | $55,377 | $96,276 | $(40,899) | (42)% | | Operating income (loss) | $2,092 | $(36,570) | +$38,662 | (106)% | | Net income (loss) | $1,513 | $(34,652) | +$36,165 | (104)% | | Net loss per share - basic & diluted| $(0.00) | $(0.04) | +$0.04 | (100)% | - Amortization expense decreased significantly by **$17.9 million (82%)** year-over-year[28](index=28&type=chunk) - Change in fair value of contingent consideration resulted in a **$15.0 million income** in Q1 FY2026, compared to zero in the prior year[28](index=28&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Condensed_Consolidated_Statements_of_Cash_Flows) Tilray significantly improved its cash flow from operations, reducing cash used by 96% year-over-year, with investing activities shifting from a net use to a net provision of cash, primarily due to marketable securities disposal Condensed Consolidated Statements of Cash Flows (in thousands of US dollars) | Activity | Q1 FY2026 (Aug 31, 2025) | Q1 FY2025 (Aug 31, 2024) | Change (YoY) | % Change (YoY) | | :-------------------------------- | :----------------------- | :----------------------- | :----------- | :------------- | | Net cash used in operating activities | $(1,341) | $(35,307) | +$33,966 | (96)% (Improvement) | | Net cash provided by (used in) investing activities | $24,467 | $(49,395) | +$73,862 | (150)% | | Net cash provided by financing activities | $19,848 | $60,590 | $(40,742) | (67)% | | Net increase (decrease) in cash and cash equivalents | $43,162 | $(23,154) | +$66,316 | (286)% | | Cash and cash equivalents, end of period | $264,828 | $205,186 | +$59,642 | +29% | - The significant improvement in investing activities was largely due to **$34.7 million** in proceeds from the disposal of marketable securities in Q1 FY2026, compared to a **$42.7 million** purchase in Q1 FY2025[30](index=30&type=chunk) [Segmental Revenue Performance](index=7&type=section&id=Segmental_Revenue_Performance) This section details Tilray's net revenue breakdown by operating segment and cannabis market channel, highlighting key growth drivers and market share dynamics [Net Revenue by Operating Segment](index=7&type=section&id=Net_Revenue_by_Operating_Segment) Tilray's total net revenue increased by 5% year-over-year, with growth primarily driven by the Distribution and Cannabis segments, while the Beverage segment remained relatively stable Net Revenue by Operating Segment (in thousands of U.S. dollars) | Segment | Q1 FY2026 (Aug 31, 2025) | % of Total Revenue (2025) | Q1 FY2025 (Aug 31, 2024) | % of Total Revenue (2024) | Change (YoY) | % Change (YoY) | | :---------------- | :----------------------- | :------------------------ | :----------------------- | :------------------------ | :----------- | :------------- | | Beverage business | $55,739 | 27% | $55,972 | 28% | $(233) | (0.4)% | | Cannabis business | $64,511 | 31% | $61,249 | 31% | +$3,262 | +5% | | Distribution business | $74,007 | 35% | $68,071 | 34% | +$5,936 | +9% | | Wellness business | $15,244 | 7% | $14,752 | 7% | +$492 | +3% | | **Total net revenue** | **$209,501** | **100%** | **$200,044** | **100%** | **+$9,457** | **+5%** | - In constant currency, total net revenue was **$204.8 million**, indicating a slight negative foreign exchange impact on reported revenue[32](index=32&type=chunk) [Net Cannabis Revenue by Market Channel](index=8&type=section&id=Net_Cannabis_Revenue_by_Market_Channel) Canadian adult-use cannabis revenue was the primary driver of growth within the cannabis segment, increasing by 12% year-over-year and significantly expanding its share of total cannabis revenue Net Cannabis Revenue by Market Channel (in thousands of U.S. dollars) | Channel | Q1 FY2026 (Aug 31, 2025) | % of Total Cannabis Revenue (2025) | Q1 FY2025 (Aug 31, 2024) | % of Total Cannabis Revenue (2024) | Change (YoY) | % Change (YoY) | | :-------------------------- | :----------------------- | :--------------------------------- | :----------------------- | :--------------------------------- | :----------- | :------------- | | Canadian medical cannabis | $6,146 | 10% | $6,261 | 10% | $(115) | (2)% | | Canadian adult-use cannabis | $64,067 | 99% | $57,235 | 94% | +$6,832 | +12% | | Wholesale cannabis | $4,155 | 6% | $5,507 | 9% | $(1,352) | (25)% | | International cannabis | $13,367 | 21% | $12,191 | 20% | +$1,176 | +10% | | Less excise taxes | $(23,224) | (36)% | $(19,945) | (33)% | $(3,279) | +16% | | **Total** | **$64,511** | **100%** | **$61,249** | **100%** | **+$3,262** | **+5%** | - In constant currency, Canadian adult-use cannabis revenue was **$64.4 million**, showing consistent growth[34](index=34&type=chunk) [Reconciliations and Key Operating Metrics](index=8&type=section&id=Reconciliations_and_Key_Operating_Metrics) This section provides reconciliations for non-GAAP financial measures such as Adjusted EBITDA, Adjusted Net Income, and Adjusted Free Cash Flow, offering deeper insights into Tilray's operational performance [Gross Margin and Adjusted Gross Margin](index=9&type=section&id=Gross_Margin_and_Adjusted_Gross_Margin) Consolidated gross margin decreased slightly year-over-year, primarily due to declines in Beverage, Cannabis, and Distribution segments, with Adjusted gross margin showing similar trends Gross Margin and Adjusted Gross Margin by Segment | Segment | Gross Margin Q1 FY2026 | Gross Margin Q1 FY2025 | Adjusted Gross Margin Q1 FY2026 | Adjusted Gross Margin Q1 FY2025 | | :---------------- | :--------------------- | :--------------------- | :------------------------------ | :------------------------------ | | Beverage | 38% | 41% | 38% | 41% | | Cannabis | 36% | 40% | 36% | 40% | | Distribution | 11% | 12% | 11% | 12% | | Wellness | 32% | 32% | 32% | 32% | | **Total** | **27%** | **30%** | **27%** | **30%** | - Purchase price accounting step-up adjustment was **$175 thousand** in Q1 FY2025, impacting adjusted gross profit[37](index=37&type=chunk) [Adjusted EBITDA Reconciliation](index=9&type=section&id=Adjusted_EBITDA_Reconciliation) Tilray's Adjusted EBITDA increased by 9% year-over-year, reaching $10.2 million, primarily due to the significant improvement in net income and reduced amortization and restructuring costs Adjusted EBITDA (in thousands of U.S. dollars) | Metric | Q1 FY2026 (Aug 31, 2025) | Q1 FY2025 (Aug 31, 2024) | Change (YoY) | % Change (YoY) | | :------------------------- | :----------------------- | :----------------------- | :----------- | :------------- | | Net income (loss) | $1,513 | $(34,652) | +$36,165 | (104)% | | Amortization | $15,561 | $31,814 | $(16,253) | (51)% | | Change in fair value of contingent consideration | $(15,000) | $0 | $(15,000) | NM | | Restructuring costs | $869 | $4,247 | $(3,378) | (80)% | | **Adjusted EBITDA** | **$10,181** | **$9,334** | **+$847** | **+9%** | [Adjusted Net Income (Loss) Per Share Reconciliation](index=10&type=section&id=Adjusted_Net_Income_Loss_Per_Share_Reconciliation) Tilray achieved a positive Adjusted Net Income of $3.9 million in Q1 FY2026, a significant improvement from a loss in the prior year, resulting in a positive Adjusted Net Income per share Adjusted Net Income (Loss) Per Share (in thousands of U.S. dollars) | Metric | Q1 FY2026 (Aug 31, 2025) | Q1 FY2025 (Aug 31, 2024) | Change (YoY) | % Change (YoY) | | :---------------------------------- | :----------------------- | :----------------------- | :----------- | :------------- | | Net loss attributable to stockholders of Tilray Brands, Inc. | $(322) | $(39,165) | +$38,843 | (99)% | | Amortization | $15,561 | $31,814 | $(16,253) | (51)% | | Change in fair value of contingent consideration | $(15,000) | $0 | $(15,000) | NM | | **Adjusted net income (loss)** | **$3,935** | **$(6,082)** | **+$10,017** | **(165)%** | | **Adjusted net income (loss) per share - basic and diluted** | **$0.00** | **$(0.01)** | **+$0.01** | **(100)%** | [Adjusted Free Cash Flow Reconciliation](index=10&type=section&id=Adjusted_Free_Cash_Flow_Reconciliation) Tilray significantly improved its adjusted free cash flow, reducing the cash outflow by 88% year-over-year, primarily driven by the substantial improvement in net cash used in operating activities Adjusted Free Cash Flow (in thousands of U.S. dollars) | Metric | Q1 FY2026 (Aug 31, 2025) | Q1 FY2025 (Aug 31, 2024) | Change (YoY) | % Change (YoY) | | :-------------------------------- | :----------------------- | :----------------------- | :----------- | :------------- | | Net cash used in operating activities | $(1,341) | $(35,307) | +$33,966 | (96)% (Improvement) | | Investments in capital and intangible assets, net | $(9,230) | $(6,708) | $(2,522) | +38% | | Free cash flow | $(10,571) | $(42,015) | +$31,444 | (75)% (Improvement) | | Add: growth CAPEX | $3,009 | $2,540 | +$469 | +18% | | Add: cash paid for litigation settlements | $2,804 | $0 | +$2,804 | NM | | **Adjusted free cash flow** | **$(4,758)** | **$(39,475)** | **+$34,717** | **(88)% (Improvement)** | [Cautionary Statement Concerning Forward-Looking Statements](index=2&type=section&id=Cautionary_Statement_Concerning_Forward-Looking_Statements) This section outlines the nature of forward-looking statements, which involve intentions, beliefs, and expectations about future events, and highlights that actual results may differ materially due to various risks and uncertainties [Forward-Looking Statements Overview](index=2&type=section&id=Forward-Looking_Statements_Overview) This section outlines the nature of forward-looking statements, which involve intentions, beliefs, and expectations about future events, and highlights that actual results may differ materially due to various risks and uncertainties - Forward-looking statements are identified by words like 'forecast,' 'future,' 'should,' 'could,' 'believe,' 'anticipate,' 'expect,' 'intend,' 'may,' 'project,' 'will,' 'would' and similar expressions[9](index=9&type=chunk) - These statements include expectations regarding becoming a leading lifestyle CPG company, achieving long-term profitability, operational scale, market share, revenue growth, margin improvements, fiscal year 2026 financial guidance (including Adjusted EBITDA), opportunities in the U.S. cannabis market, and leveraging AI strategies[10](index=10&type=chunk) - Many factors could cause actual results to differ materially from forward-looking statements, and the company does not undertake to publicly update them unless required by law[11](index=11&type=chunk)[12](index=12&type=chunk) [Corporate Information](index=2&type=section&id=Corporate_Information) This section provides details on the Q1 FY2026 financial results webcast and contact information for investor relations and media inquiries [Live Audio Webcast](index=2&type=section&id=Live_Audio_Webcast) Tilray Brands hosted a live audio webcast to discuss its Q1 FY2026 financial results, with a replay available on the company's investor relations website - Webcast held on **October 09, 2025**, at **8:30 a.m. Eastern Time**[6](index=6&type=chunk) - Available on the Events & Presentations section of Tilray's Investor Relations website, with a replay archived on the Company's website[6](index=6&type=chunk) [Contacts](index=4&type=section&id=Contacts) Contact information for investor relations and media inquiries is provided - Investor Relations: investors@tilray.com, Pro-TLRY@prosek.com[24](index=24&type=chunk) - Media: news@tilray.com[24](index=24&type=chunk)